I. Purpose

To reduce morbidity and mortality from smallpox and monkeypox by vaccinating persons who meet eligibility and risk criteria established by the Centers for Disease Control and Prevention (CDC) and Indian Health Service.

II. Policy

Gallup Service Unit (GSU) will make the JYNNEOS smallpox and monkeypox vaccine available to patients who meet risk and eligibility criteria. GSU will follow manufacturer, Food and Drug Administration (FDA), CDC, and Indian Health Service (IHS) guidelines regarding storage, handling, patient assessment, vaccine administration, and patient follow-up.

III. Background

JYNNEOS vaccine is used for the prevention of smallpox and monkeypox disease among people determined to be at high risk for infection and is licensed as a series of two doses administered 28 days (4 weeks) apart. On August 9, 2022, the FDA authorized the intradermal administration of the JYNNEOS vaccine for the management of monkeypox, which may permit five doses to be obtained out of a one-dose vial. The Emergency Use Authorization (EUA) also expanded use of the standard subcutaneous dose regimen to patients <18 years of age.

According to current CDC guidance, jurisdictional vaccine strategies should reflect national priorities to employ PEP and PEP++ strategies, with expansion to PrEP for individuals at increased risk of monkeypox from non-occupational exposure and other strategies likely to have the largest impact in slowing the current outbreak. IHS will continue to revisit criteria for monkeypox vaccination and eligibility may continue to change as supply from the federal government increases.

IV. Procedure

GSU will follow the current eligibility criteria issued by CDC and IHS and will provide the JYNNEOS vaccine to patients who meet that criteria. All patients presenting to GSU for care in the Emergency Department, Outpatient Departments, Pharmacy, Walk-in Primary Care Clinic, or admitted to an Inpatient Unit who meet the outlined criteria for immunization will be informed of the availability of the JYNNEOS vaccine. In addition, patients referred to Public Health Nursing (PHN) for a Sexual Transmitted Infection (STI) or monkeypox
follow-up will be informed of their eligibility for the JYNNEOS vaccine. Patients who agree to receive the vaccine will receive the vaccine or scheduled for an immunization appointment following clinic procedures and following the JYNNEOS Smallpox and Monkeypox Vaccine Standing Orders for Administering Vaccine: Standard Regimen or JYNNEOS Smallpox and Monkeypox Vaccine Standing Orders for Administering Vaccine: Alternative Regimen. The regimen used for vaccine administration will be based on the following criteria:

- Standard regimen (0.5 mL subcutaneous injection): patients with history of keloid scarring and all patients under 18 years of age
- Alternative regimen (0.1 mL intradermal injection): patients 18 years and older without a history of keloid scarring

All JYNNEOS vaccines will be stored and inventory managed by the Pharmacy staff. Clinics, Emergency Department, and Inpatient staff can request JYNNEOS supply from pharmacy to administer to patients.

All staff who administer the JYNNEOS vaccine will have completed training on the vaccine and have competencies documented in their employee folder.

V. Additional Resources

JYNNEOS Smallpox and Monkeypox Vaccine Standing Orders for Administering Vaccine: Standard Regimen

JYNNEOS Smallpox and Monkeypox Vaccine Standing Orders for Administering Vaccine: Alternative Regimen

CDC Interim Clinical Considerations for Use of JYNNEOS and ACAM2000 Vaccines during the 2022 U.S. Monkeypox Outbreak:
https://www.cdc.gov/poxvirus/monkeypox/health-departments/vaccine-considerations.html